The Mexico Pharmaceuticals and Healthcare Report

    • Independent 5-year pharmaceutical and healthcare industry forecasts for Mexico.
    • Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Mexican pharmaceutical and healthcare industry.
    • Competitive intelligence, Mexican pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Mexican market.

The Mexico Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2012 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.

Business Monitor International’s Mexico Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Mexican pharmaceutical and healthcare industry.

" "I like the Mexico Pharmaceuticals & Healthcare Report because it is an invaluable source of information for industry trends and forecasting, as well as for identifying new business opportunities." "
Sergio Ulloa, Assistant General Manager, Schering-Plough SA de CV, Mexico

Key Benefits of Report

    • Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Mexico to test other views – a key input for successful budgeting and strategic business planning in the Mexican pharmaceutical and healthcare market.
    • Target Business Opportunities & Risks in the Mexican Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Mexico.
    • Exploit The Latest Competitive Mexican Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Mexico.

Coverage

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.

Market Summary

Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.

Regulatory Regime

Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.

BMI 5-Year Industry Forecast

5-Year Forecasts to end-2011 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

  • Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
  • Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
  • OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
  • Generics market (US$bn)/ as % of total market
  • Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population

Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

BMI 5-Year Macroeconomic Forecasts

BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt

Competitive Landscape & Profiles

Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.

BMI's Executive Summary

[TOP]

Mexico's market continues to grow robustly in value terms, but volume growth appears to be lagging. BMI estimates 2007 market growth at 8.7% year-on-year (y-o-y), reaching a value of US$13.3bn. The new five-year forecast for the period 2007 to 2012 sees average annual growth in dollar terms of 5.4% and in local currency terms of 7.4%. According to IMS Health, the market grew 7.5% in value terms y-oy over the first seven months of 2007, whilst the number of units sold edged up only 0.7%. Local market sources indicate that volumes remain nearly static, despite record spending by the state sector.

One interpretation of this data is that Mexicans continue to pay too much for medicines, a perennial source of controversy. This is attributed, to over-concentration in distribution, corruption and inefficiency in the state sector and generally weak market oversight. Still, with the legitimate generics market thriving – to the long-term detriment of copy drugs or similares – and multinationals carrying out new launches, there is also some evidence that more effective medicines are being used in smaller volumes than older drugs. The one certainty is that with a growing population, more pensioners and a surge in the number of obese and those diagnosed with diabetes, Mexico's drugs bill will continue to rise.

With just over 50% of the population having some form of healthcare insurance – mainly through state schemes and private-sector policies – President Felipe Calderón warned in October 2007 that comprehensive universal coverage would not be achieved until 2030. At the same time, more money is going into the system – the government claims total health spending will jump 38% if it remains the same as in draft 2008 budget. One crucial pillar in coverage is the long indebted ISSSTE social security provider. In a step forward, state-run pension fund provider Afore Pensionissste. will manage wage contributions from federal workers from 2008 under legislation aimed at keeping the system solvent.

How much state funding goes to medicines will depend on the ability of the authorities to efficiently manage purchasing. The development of the market will also depend on continued improvements of the intellectual property (IP) environment. In BMI's new Business Environment Rankings for the Americas, Mexico scores third after the US and Canada, reflecting its relatively strong IP protections and continued growth potential. The opening of a new oncology medicines plant by Swiss drugmaker Roche in Toluca, representing a US$60mn investment underlines the attractiveness of the market.

But there is still room for improvement. In October, trade body La Asociación Mexicana de Industrias de Investigación Farmacéutica (AMIFA) called for stronger data protection under Mexico's North American Free-Trade Agreement (NAFTA) commitments. One reason for deficiencies is the lack of research and development (R&D) work by both the local private sector and state institutions, driving dependence on copy drugs and generics. Some 98% of patents are of foreign origin, a dismal rate by even emerging market standards. Arguably, the lack of an industrial policy for the sector – such as the twin generics and R&D strategies pursued in Brazil – will leave local players fighting a constant rearguard action against tighter rules and, crucially, better enforcement.

Contents

[TOP]

Chapter 1 - Executive Summary

Mexico Pharmaceuticals & Healthcare Industry SWOT

Mexico Political SWOT

Mexico Economic SWOT

Mexico Business Environment SWOT

Chapter 2 - Mexico: Business Environment Ranking

Table: Latin America: Business Environment Ranking

Business Environment Ranking

Economics - Long-Term Risk

Politics - Long-Term Risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 3 - Mexico: Market Summary

Chapter 4 - Regulatory Regime

Intellectual Property Environment

Table: Mexican marketing applications in alleged violation of patent rights

Pricing & Reimbursement Issues

Other Regulatory Developments

Chapter 5 - Industry Developments

Pharmaceutical Market Trends

Healthcare Sector

Table: Private Health Insurance In Mexico

Pharmaceutical Sector

Generics Sector

Multinational Sector Activity

R&D Sector

Table: Clinical Research In Mexico, 2003-2004

Table: Clinical Studies In Mexico By Therapeutic Area, 2004

Chapter 6 - Industry Forecast Scenario

Overall Market Forecast

Table: Drug market trends

Key Growth Factors - Industry

Table: Health expenditure indicators

Key Growth Factors - Macroeconomic

Table: Economic Activity Indicators

Prescription Market Forecast

Table: Prescription market forecasts

OTC Market Forecast

Table: Mexico: OTC Categories

Table : OTC market forecast

Generics Market Forecast

Table: Generic Market Forecast

Table: Branded Market Forecast

Export/Import Forecasts

Table: Sectoral trade indicators

Table: Healthcare Sector Data & Forecasts

Key Risks To BMI's Forecast Scenario

Chapter 7 - Company Monitor

Profiles: Leading Foreign Companies

Pfizer

GlaxoSmithKline

Sanofi-Aventis

Eli Lilly

Bristol-Myers Squibb

Novartis Farmaceutica

Bayer

Boehringer-Ingelheim Promeco

Merck KGaA

Roche

Indigenous Manufacturer Profile

Liomont

Chapter 8 - Latin America: Regional Market Overview

BMI Forecast Modelling

How We Generate Our Industry Forecasts

Technical Process

Pharmaceutical Industry

Sources

Chapter 9 - Appendix: Regional Demographic Data

Wages (ave per annum), US$

Population

Household Spending Per Capita, US$

Private Consumption Per Capita, US$ PPP

Market Size, GDP, US$bn

Chapter 10 - Country Snapshot: Mexico Demographic Data

Section 1: Population

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Section 3: Labour Market And Spending Power

Table: Employment Indicators

Table: Consumption and Stratification

Table: Wages per year

Competitive Landscape for Latin America Pharmaceuticals and Healthcare: Sample of Companies Ranked

[TOP]

Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.

Network of Latin American Pharmaceuticals & Healthcare Sources

[TOP]

BMI's Latin American Pharmaceuticals & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceuticals industry associations, chambers of commerce and company reports. Information sources include:

 

Read about our other Pharmaceuticals & Healthcare Reports

Asia Europe Middle East & Africa The Americas
UK
UAE
USA
[top]

 

Business Monitor International
A Market Leader in Country Risk, Industry Intelligence and Company Research

Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK

BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world.

Country Risk Analysis and Forecasts
BMI
has for 24 years specialised in political risk analysis, financial markets analysis, and macroeconomic forecasts on 175 global markets.

Industry Intelligence and Market Research
BMI's industry research covers Automotives; Banking; Chemicals; Defence & Security; Food & Drink; Freight Transport; Information Technology; Infrastructure; Insurance; Mining; Oil & Gas; Petrochemicals; Pharmaceuticals & Healthcare; Power; Telecommunications, and Tourism.

Company Research
BMI maintains a fully-researched 55,000-site database of multinational company subsidiaries located across global markets.